---
input_text: "[Clinical Analysis of Salvage Treatment of Glucocorticoid Resistant Graft-Versus-Host
  Disease with Vedolizumab in Children]. OBJECTIVE: To investigate the efficacy and
  safety of VDZ (Vedolizumab) in the salvage treatment of glucocorticoid resistance
  to gastrointestinal graft-versus-host disease (GR-GI GVHD) after allogeneic hematopoietic
  stem cell transplantation (allo-HSCT) in children. METHODS: The clinical data of
  5 patients with refractory GI GVHD who received allo-HSCT in Wuhan Children's Hospital
  from December 2020 to December 2021 were retrospectively analyzed with VDZ salvage
  therapy. RESULTS: Among the 5 children with refractory GI GVHD, there were 1 male
  and 4 female, including 2 cases of extremely severe aplastic anemia, 1 case of acute
  myeloid leukemia (M2, high-risk), 1 case of fanconi anemia and 1 case of myelodysplastic
  syndrome. The median age of transplant recipients was 54.4 (12-164) months. The
  median treatment time from transplantation to VDZ was 1.4 (0.6-6.8) months. On average,
  3.5 (2-5) doses of VDZ were received. After receiving treatment, 2 patients achieved
  a complete response (CR), 2 patients achieved a very good partial response (VGPR),
  1 patient was non-responsive (NR) after a short-term partial response (PR). Compared
  with that before VDZ treatment, the amount of diarrhea, stool color, blood and traits
  of the children after medication were effectively improved. The median follow-up
  time was 9.3 (7.23-12.83) months. No disseminated or severe bacterial/fungal infections
  occurred during VDZ treatment and follow-up, and 2 children died of leukemia recurrence
  and pulmonary bronchiolitis obliterans. CONCLUSION: VDZ salvage treatment of refractory
  GI GVHD in children has obvious short-term efficacy and good safety."
raw_completion_output: |-
  primary_disease: Glucocorticoid Resistant Graft-Versus-Host Disease (GR-GI GVHD)

  medical_actions: Salvage treatment with Vedolizumab (VDZ); Allogeneic hematopoietic stem cell transplantation (allo-HSCT)

  symptoms: Diarrhea; Stool color; Blood in stool

  chemicals: Vedolizumab

  action_annotation_relationships: Salvage treatment with Vedolizumab (VDZ) TREATS Diarrhea IN Glucocorticoid Resistant Graft-Versus-Host Disease (GR-GI GVHD); Salvage treatment with Vedolizumab (VDZ) TREATS Stool color IN Glucocorticoid Resistant Graft-Versus-Host Disease (GR-GI GVHD); Salvage treatment with Vedolizumab (VDZ) TREATS Blood in stool IN Glucocorticoid Resistant Graft-Versus-Host Disease (GR-GI GVHD)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Salvage treatment with Vedolizumab (VDZ) TREATS Blood in stool IN Glucocorticoid Resistant Graft-Versus-Host Disease (GR-GI GVHD)

  ===

extracted_object:
  primary_disease: Glucocorticoid Resistant Graft-Versus-Host Disease (GR-GI GVHD)
  medical_actions:
    - Salvage treatment with Vedolizumab (VDZ)
    - MAXO:0001479
  symptoms:
    - HP:0002014
    - Stool color
    - HP:0025085
  chemicals:
    - Vedolizumab
  action_annotation_relationships:
    - subject: Salvage treatment with Vedolizumab (VDZ)
      predicate: TREATS
      object: HP:0002014
      qualifier: Glucocorticoid Resistant Graft-Versus-Host Disease (GR-GI GVHD)
      subject_extension: Vedolizumab
    - subject: Salvage treatment
      predicate: TREATS
      object: Stool color
      qualifier: Glucocorticoid Resistant Graft-Versus-Host Disease
      subject_qualifier: with Vedolizumab (VDZ)
      subject_extension: Vedolizumab
    - subject: Salvage treatment
      predicate: TREATS
      object: HP:0025085
      qualifier: Glucocorticoid Resistant Graft-Versus-Host Disease
      subject_qualifier: with Vedolizumab (VDZ)
      subject_extension: Vedolizumab
named_entities:
  - id: MONDO:0019391
    label: Fanconi anemia
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplantation (HSCT)
  - id: CHEBI:18198
    label: ADCs
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: MAXO:0000750
    label: conditioning regimens
  - id: CHEBI:37153
    label: Calcineurin inhibitor
  - id: CHEBI:38215
    label: Calcium channel blocker
  - id: CHEBI:4031
    label: Cyclosporine
  - id: CHEBI:8069
    label: Phenobarbital
  - id: CHEBI:2668
    label: Amlodipine
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: MAXO:0000016
    label: Cellular therapy
  - id: HP:0001871
    label: Blood dyscrasias
  - id: MAXO:0000595
    label: Radiography
  - id: HP:0005528
    label: Bone marrow failure
  - id: HP:0034057
    label: Congenital defects
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:44185
    label: Methotrexate
  - id: MONDO:0005233
    label: Non-small cell lung cancer (NSCLC)
  - id: CHEBI:33364
    label: Platinum
  - id: MAXO:0000647
    label: chemotherapy
  - id: HP:0030358
    label: Non-small cell lung cancer
  - id: MAXO:0001479
    label: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  - id: HP:0002863
    label: Myelodysplasia
  - id: HP:0001909
    label: Leukemia
  - id: MONDO:0016624
    label: Hereditary anemia
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0005570
    label: Hematological disorders
  - id: HP:0002664
    label: cancer
  - id: MONDO:0015253
    label: Diamond Blackfan anemia
  - id: MAXO:0000600
    label: Kidney replacement therapy (KRT)
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003259
    label: Elevated serum creatinine (SCr > 100micromol/l)
  - id: MONDO:0001529
    label: Bone marrow failure (BMF)
  - id: HP:0002860
    label: oral squamous cell carcinoma (SCC)
  - id: MONDO:0100339
    label: Fanconi anemia (FA)
  - id: CHEBI:28680
    label: Ara-C
  - id: CHEBI:27899
    label: Cisplatin
  - id: HP:0011793
    label: Malignant tumors
  - id: HP:0000818
    label: Endocrinopathies
  - id: HP:0002745
    label: Oral leukoplakia
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:61049
    label: Tacrolimus
  - id: HP:0002910
    label: elevated liver function tests
  - id: CHEBI:125354
    label: plerixafor
  - id: CHEBI:231614
    label: Nivolumab
  - id: CHEBI:25016
    label: PBS
  - id: MONDO:0009693
    label: Multiple Myeloma
  - id: CHEBI:28876
    label: Melphalan
  - id: CHEBI:229764
    label: Selinexor
  - id: CHEBI:229762
    label: Eltanexor
  - id: HP:0006775
    label: Multiple Myeloma
  - id: CHEBI:229763
    label: exportin 1 inhibitors
  - id: MONDO:0015909
    label: aplastic anemia
  - id: HP:0004808
    label: Acute myeloid leukaemia
  - id: MAXO:0000004
    label: Surgery
  - id: MAXO:0000014
    label: Radiotherapy
  - id: MONDO:0001881
    label: Septic shock
  - id: MAXO:0001021
    label: Antimicrobial treatment
  - id: MAXO:0000174
    label: Antifungal treatment
  - id: HP:0001876
    label: Pancytopenia
  - id: HP:0001945
    label: Fever
  - id: CHEBI:133748
    label: Citrate
  - id: CHEBI:41879
    label: Dexamethasone
  - id: CHEBI:33281
    label: Antimicrobial
  - id: CHEBI:35718
    label: Antifungal
  - id: MONDO:0044033
    label: Posterior reversible encephalopathy syndrome (PRES)
  - id: MAXO:0010030
    label: Bone marrow transplantation
  - id: MAXO:0001188
    label: Laparoscopy
  - id: HP:0000988
    label: Skin rash
  - id: MONDO:0010161
    label: Tyrosinemia Type 1
  - id: HP:0001919
    label: acute kidney injury (AKI)
  - id: HP:0000822
    label: hypertension
  - id: MAXO:0001298
    label: therapy
  - id: HP:0040012
    label: Increased chromosomal breakage
  - id: MONDO:0004631
    label: Tongue cancer (TC)
  - id: CHEBI:4735
    label: EDTA
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0025085
    label: Blood in stool
